BGPT: Paper Review: β-Chemokine Receptor CCR5 Signals through SHP1, SHP2, and Syk

Fuel Your Discoveries

Quick Explanation Copied

Core claim (paper)

MIP1β-activated CCR5 forms (or promotes) a complex linking RAFTK (a.k.a. Pyk2/CAK-β), Syk, SHP1, and Grb2, with SHP1/SHP2 tyrosine phosphorylation occurring after stimulation and orthovanadate-sensitive chemotaxis indicating functional importance of tyrosine phosphatases in this CCR5 → migration axis.

Source: 10.1074/jbc.M000689200

Long Explanation

β-Chemokine Receptor CCR5 Signals through SHP1, SHP2, and Syk

Rigor-first paper review (skeptical, mechanistic, evidence-weighted)

DOI: 10.1074/jbc.M000689200

1) What the authors claim (tight chain)

MIP1β stimulation of CCR5 increases tyrosine phosphorylation of SHP1 and SHP2 in CCR5 L1.2 transfectants and also in activated T-cells (with reduced magnitude in T-cells attributed in the text to receptor density and/or cell-type differences).
SHP1 associates with RAFTK constitutively and modestly increases upon stimulation.
RAFTK mutant RAFTK m906 (Tyr906→Phe) does not mediate the MIP1β-induced phosphorylation of SHP1/SHP2.
Orthovanadate markedly abolishes MIP1β-induced chemotaxis, consistent with an important role for tyrosine phosphatase activity in the migration phenotype.
Syk is activated (autophosphorylation activity increased) following MIP1β stimulation, and Syk associates with RAFTK and also with SH2-domain adaptors including Grb2.
RAFTK m402 (dominant-negative Src-binding site) attenuates Syk activation, while wild-type RAFTK overexpression enhances Syk activity—supporting RAFTK as an upstream regulator of Syk in this CCR5 signaling context.
Together, authors propose a signaling complex that includes RAFTK, Syk, SHP1, and Grb2 downstream of CCR5 upon ligand binding.

2) Visual map: proposed CCR5→migration signaling (paper’s model)

Evidence for this model is assembled from the paper’s phosphorylation, immunoprecipitation/association, mutant RAFTK logic, and orthovanadate chemotaxis results as described in the main Results/Discussion.

3) Quantitative anchor: orthovanadate inhibition of CCR5-mediated chemotaxis (from paper figure text)

The paper states dose-dependent chemotaxis attenuation by orthovanadate (CCR5 L1.2: ~85% inhibition at 100 µM; activated T-cells: ~70% inhibition at 100 µM), supporting an orthovanadate-sensitive role for tyrosine phosphatases in the migratory response.

Skeptical note: only the 100 µM inhibition values are explicitly available in the excerpt; intermediate doses are not numerically specified here, so the plot intentionally leaves them blank rather than inventing points.

4) Evidence grading by claim component (what is strong vs what is more inferential)

Claim component	Evidence type in paper	Directness	Skeptical caveat
MIP1β induces SHP1/SHP2 tyrosine phosphorylation	IP + Western with anti-phosphotyrosine and re-blot for SHP1/SHP2 amounts	Strong	Magnitude differs between CCR5 L1.2 vs primary/activated T-cells; authors suggest receptor density/cell-type differences.
SHP1 associates with RAFTK; increased modestly after stimulation	Co-association (IP/IB) and GST fusion binding	Moderate→strong	Association ≠ functional causality; RAFTK’s non-mediation of SHP1/2 phosphorylation addresses part of this.
RAFTK m906 does not mediate SHP1/SHP2 phosphorylation	Dominant-negative RAFTK mutant logic (Tyr906→Phe)	Strong	Mutant interpretation depends on expression level and specificity of disrupting phosphatase-binding.
Orthovanadate abolishes MIP1β-induced chemotaxis	Transwell migration after phosphatase inhibition + viability noted unchanged	Moderate	Orthovanadate is broad; it supports functional involvement of tyrosine phosphatases but not which phosphatase(s) causally drive migration.
Syk is activated and associates with RAFTK/Grb2	Syk activation assay (autophosphorylation) + IP/IB associations	Strong	Association-based complex model remains partly correlative regarding order of events in endogenous cells.
RAFTK acts upstream of Syk	RAFTK m402 (Src-binding site) attenuates Syk; WT RAFTK enhances Syk	Moderate→strong	Overexpression can shift stoichiometries; mutant effects assume RAFTK→Src→Syk coupling in this system.

All table entries summarize directly from the paper’s experimental statements in the provided full text.

5) Key limitations / blind spots (what could change the interpretation)

Cell-model specificity: the strongest signaling readouts are in CCR5 L1.2 transfectants and activated T-cells; the excerpt itself notes reduced phosphorylation magnitudes in T-cells, attributed to receptor density and/or cell-type differences, which could limit direct quantitative extrapolation.
Phosphatase inhibitor breadth: orthovanadate is not selective for SHP1 vs SHP2 vs other tyrosine phosphatases; thus, chemotaxis inhibition supports “phosphatase activity matters” but is not sufficient to prove SHP1/SHP2 are the unique causal drivers.
Complex vs causation: the proposed multi-protein complex (RAFTK–Syk–SHP1–Grb2) is built from association and functional mutant effects, but further perturbation (e.g., direct disruption of specific SHP1/SHP2–binding motifs) is not shown in the provided excerpt.
Temporal ordering is inferred: RAFTK mutant logic supports RAFTK upstream of Syk activation, yet the exact sequence of molecular assembly/activation in real-time endogenous CCR5 signaling is not directly resolved.

6) How to falsify the main model (minimal “what would break it”)

Disprove CCR5→SHP1/SHP2 link: show that MIP1β stimulation does not increase SHP1/SHP2 tyrosine phosphorylation in CCR5-expressing cells.
Disprove RAFTK is upstream of Syk: show that RAFTK m402 and RAFTK WT overexpression do not respectively attenuate or enhance Syk activation under conditions matching the paper’s system.
Disprove orthovanadate link: show that chemotaxis is not substantially reduced by phosphatase inhibition in this same experimental setup.
Disprove complex stoichiometry: show that preventing SHP1 or Grb2 docking disrupts the observed Syk activation/chemotaxis phenotypes (the excerpt supports docking by association, but more direct docking disruption is not presented here).

These falsification targets correspond to the specific experimental handles the paper used (phosphorylation assays, RAFTK mutants, orthovanadate chemotaxis inhibition, and association readouts).

Optional: targeted BGPT follow-ups (Author Reviews)

Feedback:

Updated: April 12, 2026